Venlafaxine: OOS result for Spheroids Dissolution Rate Profile (DRP)
Brand(s)
Last updated
Summary
Product
TARO-VENLAFAXINE XR
Issue
Health products - Product quality
What to do
See instructions below.
Affected products
Brand |
Product Name |
Market Authorisation |
Dosage Form |
Strength |
Lot |
|---|---|---|---|---|---|
TARO-VENLAFAXINE XR |
TARO-VENLAFAXINE XR CAP 150MG |
DIN 02380099 |
Capsule |
Venlafaxine Hydrochloride Extended-Release Capsules 150 mg |
AB00434 |
Issue
Out of specification result for Spheroids Dissolution Rate Profile (DRP)
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Related recalls and alerts
Additional information
Background
Depth of Recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Recalling Firm: Sun Pharma Canada Inc. (formerly Ranbaxy Pharmaceuticals Canada Inc.) 126 East Drive, Brampton, ON, L6T 1C1
Published by
Health Canada
Audience
General public
Retail
Recall class
Type II
Identification number
RA-64571
Get notified
Receive notifications for new and updated recalls and alerts by category.